Publications

2016 publications by members of the Bill Walsh Lab

Parker, N.R., Hudson, A.L.*, Khong, P., Parkinson, J.F., Dwight, T., Ikin, R.J., Zhu, Y., Cheng, Z.J., Vafaee, F., Chen, J., Wheeler, H.R. and Howell, V.M. (2016) Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep, accepted (17th Feb). IF 5.578. *Joint 1st author.

Hudson, A.L. and Colvin, E.K. (2016) Transgenic mouse models of SV-40-induced cancer. ILAR journal, accepted (7th Jan). IF 2.393.

2015 publications by members of the Bill Walsh Lab

Ashton, A.W., Le, T.Y.L., Gomez-Sanchez, C.E., Morel-Kopp, C., McWhinney, B., Hudson, A.L., Mihailidou, A.S. (2015) Role of non-genomic signalling pathways activated by aldosterone during cardiac reperfusion injury. Mol Endocrinol, 29, 1144-1155.

Weir, C.J., Hudson, A.L., Peters, L. and Howell, V.M. (2015). Orthotopic implantation and peripheral immune cell monitoring in the II-45 syngeneic rat mesothelioma model. Jove, 104, e53019.

Parker NR, Khong P, Parkinson JF, Howell VM and Wheeler HR. (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front. Oncol. eCollection, accepted.

Davis ID, Long A, Yip S, Martin A, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR. (2015) EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, accepted.

Al Khamici H, Brown LJ, Hossain KR, Hudson AL, Sinclair-Burton AA, Ng JP, Daniel EL, Hare JE, Cornell BA, Curmi PM, Davey MW, Valenzuela SM. (2015) Members of the chloride intracellular ion channel protein family demonstrate glutaredoxin-like enzymatic activity. PLoS One, 10, e115699.

Diakos CI, Charles KA, Chua W, Howell VM, Clarke SJ. (2015) Biomarkers in metastatic colorectal cancer: Predicting prognosis and therapeutic response. In Biomarkers in Disease: Methods, Discoveries and Applications. V.R. Preedy, Ed.; Springer: New York, (ISBN 978-94-007-7681-4)

Kan CWS, Howell VM, Hahn M, Marsh DJ. (2015) Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes, Chromosomes Cancer. 54(1):1-19

Ip JC, Pang TC, Glover AR, Soon P, Zhao JT, Clarke S, Robinson BG, Gill AJ, Sidhu SB. (2015) Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers. Oncologist. 2015 Feb 5. pii: theoncologist.2014-0392. [Epub ahead of print]

Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. (2015) Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia Pac J Clin Oncol. 11(1):85-92.

Zhou J, Belov L, Chapuis P, Chan C, Armstrong N, Kaufman KL, Solomon MJ, Clarke SJ, Christopherson RI. (2015) Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. J Immunol Methods. 416:59-68.

Tan CS, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ. (2015) The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer. 23(2):385-91.

2014 publications by members of the Bill Walsh Lab

Hudson, AL, Weir, C, Moon, E, Harvie, R, Klebe, S, Clarke, SJ, Pavlakis, N. and Howell, V.M. (2014) Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep. 4, 6152.

Howell VM. (2014) Mice and men working together for over 100 years in the fight against cancer. Semin Cell Dev Biol. 27:52-3.

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern Pathology 2014 27, 644–650

Howell VM and Colvin EK Genetically engineered insertional mutagenesis in mice to model cancer: Sleeping Beauty. Methods Mol Biol. 2014;1194:367-83.

Holt DE, Henthorn P, Howell VM, Robinson BG and Benn DE. (2014) Succinate Dehydrogenase Subunit D (SDHD) and Succinate Dehydrogenase Subunit B (SDHB) Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. J Comp Pathol. 151(1):25-34.

Fuller, ES. and Howell, VM (2014). Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Front Oncol. 4:57.

Howell VM. (2014) Genetically engineered mouse models for epithelial ovarian cancer: are we there yet? Semin Cell Dev Biol. 27:106-17.

Vardy J, Dhillon HM, Pond GR, Rourke SB, Xu W, Dodd A, Renton C, Park A, Bekele T, Ringash J, Zhang H, Burkes R, Clarke SJ, Tannock IF. (2014) Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol. 25(12):2404-12.

Chik JH, Zhou J, Moh ES, Christopherson R, Clarke SJ, Molloy MP, Packer NH. (2014) Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. J Proteomics. 108:146-62.

Weir, C, Hudson, AL, Moon E, Ross A, Alexander M, Peters L, Langova V, Clarke SJ, Pavlakis N, Davey R and Howell VM (2014) Streptavidin: A novel immunostimulant for the selection and delivery of autologous and synegenic tumor vaccines. Cancer Immunol Res, 2, 469-79.

Diakos CI, Charles KA, McMillan DC, Clarke SJ. (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15(11):e493-503.

Ip JC, Pang TC, Glover AR, Soon P, Clarke S, Richardson A, Campbell P, Robinson BG, Sidhu SB.(2014) Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. Ann Surg Oncol. 2014 Oct 16. [Epub ahead of print]

Colvin, EK, Weir, C, Ikin, RJ and Hudson, AL (2014) SV40 TAg mouse models of cancer. Semin Cell Dev Biol, 27C, 61-73.

Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. (2015) Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 12(5):317-24.

Kao SC, van Zandwijk N, Clarke S. (2014) Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’. Br J Cancer. 111(12):2376.

Kohonen-Corish MR, Tseung J, Chan C, Currey N, Dent OF, Clarke S, Bokey L, Chapuis PH. (2014) KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer. 134(12):2820-8.

Hayes, SA, Hudson, AL, Clarke, SJ, Molloy, MP and Howell, VM (2014) From mice to men: GEMMs as trial patients for new NSCLC therapies. Semin Cell Dev Biol, 27C, 118-127.

Paik JY, Toon CW, Benn DE, High H, Hasovits C, Pavlakis N, Clifton-Bligh RJ, Gill AJ. (2014) Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol. Feb 20;32(6):e10-3.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. (2014) Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. Sep 22;9:CD008218.

Linton A, Pavlakis N, O’Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. (2014) Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 111(9):1860-9.

Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon CW, Raut A, O’Toole SA, Cooper WA, Pavlakis N, Mead S, Chou A, Gill AJ. (2014) EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology. 46(6):501-8.

Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. (2014) Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther. 14(12):1477-93.

Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M. (2014) Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia Pac J Clin Oncol. 10(3):273-8.

Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N. (2014) The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer. 111(6):1122-31.

Toon CW, Hasovits C, Paik J, Field M, Chou A, Hugh TJ, Pavlakis N, Gill AJ. (2014) Skin rash, a kidney mass and a family mystery dating back to World War II. Med J Aust. 201(1):58-60.

Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC. (2014) Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clin Cancer Res. 20(15):4047-58.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clarke SJ, Swarbrick A, Daly RJ, Horvath LG. (2014) Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 110(10):2462-71.

Cooper W, Fox S, O’Toole S, Morey A, Frances G, Pavlakis N, O’Byrne K, Dettrick A, Leong T, Rathi V, Spagnolo D, Hemmings C, Singh M, Moffat D, Tsao MS, Wilner K, Buller R, Pitman Lowenthal S, Arifeen S, Binko J, Alam M. (2014) National Working Group Meeting on ALK diagnostics in lung cancer. Asia Pac J Clin Oncol. 10 Suppl 2:11-7.

Wang F, Gill AJ, Neale M, Puttaswamy V, Gananadha S, Pavlakis N, Clarke S, Hugh TJ, Samra JS. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 21(6):1937-47.

Paik JY, Toon CW, Benn DE, High H, Hasovitz C, Pavlakis N, Clifton-Bligh RJ, Gill AJ. (2014) Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol. 32(6):e10-3.

Govi S, Christie D, Mappa S, Marturano E, Bruno-Ventre M, Messina C, Medina EA, Porter D, Radford J, Heo DS, Park Y, Pro B, Jayamohan J, Pavlakis N, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group. (2014) The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). Leuk Lymphoma. 55(8):1796-9.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. (2014) PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer–results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 20(3):744-53.

2013 publications by members of the Bill Walsh Lab

Parker NP, Correia N, Crossley B, Buckland ME, Howell VM and Wheeler HR. Correlation of MicroRNA 132  Up-regulation with an  Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology. 2013 Dec; 6(6), 742-748.

Jankova L, Dent OF, Chan C, Chapuis P, Clarke SJ. Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer specific survival after curative resection of node-positive colorectal cancer. BMC Cancer. 2013 Oct 1;13(1):442.

Diakos CI, Chua W, Charles, KA, Howell VM and Clarke SJ. Predicting chemotherapeutic response and toxicity in colorectal cancer. Colorectal Cancer 2013 2(4): 333-345.

Stein R, Sharpe L, Boyle F, Dunn S and Clarke SJ. A randomised controlled trial of a structured intervention to facilitate end-of-life decision-making in patients with advanced cancer. J Clin Oncol 2013 31(27): 3403-3410.

Linton A, Pond G, Clarke S, Vardy J, Galsky M and Sonpavde G. Glasgow Prognostic Score as a prognostic factor with metastatic castration-resistant prostate cancer receiving docetaxel-based chemotherapy. Clin Genitourinary Cancer. 2013 Dec 11(4): 423-30

Toon CW, Walsh MJ, Chou A, Dapper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C Young JP, Win AK, Hopper JL, Crook A, on Deimling A, Jenkins MA, Buchanan DB, Gill AJ. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome. Am J Surg Pathol. 2013 Oct;37(10): 1592-602.

Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 2013 Sep;81(3):422-7.

Kacevska M, Mahns A, Sharma R, Clarke SJ, Robertson GR, Liddle C. Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signaling.  Pharm Res. 2013 Sep;30(9):2270-8.

Guthrie GJ, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based Neutrophil-Lymphocyte Ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30.

Tang JZ, Carmichael CL, Shi W, Metcalf D, Ng AP, Hyland CD, Jenkins NA, Copeland NG, Howell VM, Zhao ZJ, Smyth GK, Kile BT, Alexander WS. Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci USA 2013 110(15):6091-6.

Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013 31(10):1348-56.

Wauters E, Sanchez-Arevalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Ngawi Njicop E, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I. Sirtuin-1 regulates acinar to ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Research 2013 73(7): 2357-67.

Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther. 2013 13(5):597-611.

Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013 14(6):543-51.

Vickers MM, Karapetis CS, Tu D, O’Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013 24(4):953-60.

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ; Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer 2013 108(4):771-4.

Kao SC, Vardy J, Chatfield M, Pavlaklis N, Corte P, Clarke CW, van Zandwijk N, Clarke SJ. Validation of prognostic factors in malignant pleural mesothelioma – A retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer 2013 14; 70-77.

Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hemat 2013 85, 121–135.

Elens L, Nieuweboer A, Clarke SJ, Charles K, de Graan A, Haufroid V, Mathijssen RHJ and van Schaik RHN. (2013) The new CYP3A4 intron 6 SNP (CYP3A4*22) encodes lower CYP3A4 activity, as measured with CYP3A Phenotyping Probes Midazolam and Erythromycin. Pharmacogenomics 14(2):137-49.

Elens L, Nieuweboer A, Clarke SJ, Charles K, de Graan A, Haufroid V, Mathijssen RHJ and van Schaik RHN. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics 2013 23(3):148-55.

Clarke S, Burge M, Cordwell C, Gibbs P, Reece W and Tebbutt N. An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]. BMC Cancer 2013 13(1):120.

Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S and Pavlakis N. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer 2013 21: 697-705.

Vardy J, Dhillon HM, Clarke SJ, Olesen I, Leslie F, Warby A, Beith J, Sullivan A, Hamilton A, Beale P, Rittau A and McLachlan A. Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springer Plus 2013 2:126.

Kao SC, Clarke SJ, Vardy J, Corte P, Clarke CW, van Zandwijk N. Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Internal Med J 2013 413:402-410.

Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S and van Zandwijk N. Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 2013 14: 164-171.

Kao SC, van Zandwijk N, Corte P, Clarke C, Clarke SJ, Vardy J. Use of cancer therapy at the end of life in malignant pleural mesothelioma patients. Support Cancer Care 2013 21:1879-1884.

Li AE, Li BT, Ng BHK, McCormack S, Vedelago J, Clarke S, Pavlakis N, Samra J. Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. World Journal of Oncology 2013 4(2):74-82.